Japan fund JIC plans to sell JSR to Mitsui Chemicals, sources say

By Reuters News

- Japan Investment ‌Corp (JIC), a state-backed fund, plans to sell chipmaking materials maker JSR to Mitsui Chemicals 4183.T in a deal that could exceed 1.3 trillion yen ($8.20 billion), two people familiar with the matter said.

A decision could come as soon as within the month, one of the people said. Both people declined to be identified as the information is not public.

JIC, JSR and Mitsui Chemicals did not reply to a request for comment.

Reuters, which previously reported JIC is considering selling JSR, is reporting the final buyer for the first time.

JIC acquired JSR for some 900 billion yen two years ago and had said it planned to use the business to drive consolidation in the semiconductor materials sector.

The fund will instead sell JSR to a domestic chemical major as it takes advantage of a lift in the valuation of chip-related firms due to a boom in AI investment.

JSR, established in 1957, is a leading manufacturer of photoresists which are used to transfer circuit patterns onto semiconductor wafers.

Mitsui Chemicals, which is also expanding its chip materials business, has a market capitalisation of about 800 billion yen.

The deal could be among the largest in Japan's chemicals sector, exceeding the 2020 acquisition of Hitachi Chemical by Showa Denko which created Resonac Holdings 4004.T.

Mitsui Chemicals had 217.8 billion yen in cash and cash equivalents and 876.4 billion yen in interest-bearing debt as at the end of June.

Its debt-to-equity ratio, a measure of financial soundness, stood at 0.75.

JIC, which is overseen by the trade ministry, was set up in 2018 to invest in companies with the goal of boosting Japan's competitiveness.

Its investments include medical equipment maker Topcon alongside private equity firm KKR KKR.N.


($1 = 158.5200 yen)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.